
Laboratorio Reig (RJF) | Stock Overview & Key Data
Laboratorio Reig Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €55.00 on November 25, 2002
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Dividend Information
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Laboratorio Reig RJF | 240.10M Mid-cap | 2.03% | 1.68% | 1.00% | 14.83% | 17.51% | 9.49% | 8.70% | -20.84% |
Laboratorios ROVI | 2.72B Large-cap | -2.03% | -3.37% | 3.41% | -4.32% | -17.03% | -32.16% | 1.36% | 86.38% |
Almirall S.A ALM | 2.20B Large-cap | -3.21% | -4.12% | 0.20% | 13.15% | 22.20% | 14.03% | 4.28% | 7.11% |
Faes Farma S.A FAE | 1.31B Large-cap | -3.21% | -5.80% | -0.24% | 15.30% | 20.23% | 19.89% | 7.11% | 21.97% |
Labiana Health S.A LAB | 28.16M Small-cap | 4.32% | 15.57% | 19.14% | 33.10% | 31.29% | 22.58% | 6,233.33% | 1,051.52% |
Grifols, S.A GRF | 7.93B Large-cap | -2.06% | 22.50% | 57.28% | 54.08% | 35.84% | 46.52% | -6.61% | -47.55% |
Ownership & Short Interest
Laboratorio Reig Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Laboratorio Reig would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RJF's 52-week high and low?
- In the last 52 weeks, Laboratorio Reig reached a high of €3.40 (on June 6, 2025) and a low of €2.46 (on January 16, 2025).
- What is the market cap and P/E ratio for RJF?
- Curious about Laboratorio Reig's size and valuation? Its market capitalization stands at 240.10M. When it comes to valuation, the P/E ratio (trailing twelve months) is 42.14, and the forward P/E (looking ahead) is 14.05.
- Does RJF pay dividends? If so, what's the yield?
- Yes, Laboratorio Reig is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.61%, and the company has paid an average of €0.38 per share annually over the past 3 years.
- Who are Laboratorio Reig's main competitors or similar companies to consider before investing?
When looking at Laboratorio Reig, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Laboratorios
ROVI2.72B Healthcare Drug Manufacturers - Specialty & Generic -32.16% 1.36% Almirall S.A
ALM2.20B Healthcare Drug Manufacturers - Specialty & Generic 14.03% 4.28% Faes Farma S.A
FAE1.31B Healthcare Drug Manufacturers - Specialty & Generic 19.89% 7.11% Labiana Health S.A
LAB28.16M Healthcare Drug Manufacturers - Specialty & Generic 22.58% 6,233.33% Grifols, S.A
GRF7.93B Healthcare Drug Manufacturers - General 46.52% -6.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Laboratorio Reig Jofre S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Laboratorio Reig's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 3.03%, the Debt to Equity ratio from the most recent quarter is 31.04, and its Gross Profit Margin stands at 58.43%.
- What is the recent revenue and earnings growth for RJF?
- Looking at Laboratorio Reig's growth, its revenue over the trailing twelve months (TTM) was €336M. Compared to the same quarter last year (YoY), quarterly revenue grew by -9.00%, and quarterly earnings saw a YoY growth of 110.83%.
- How much of RJF stock is held by insiders and institutions?
- Wondering who owns Laboratorio Reig stock? Company insiders (like executives and directors) hold about 77.76% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 4.21%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.